PCBL Chemical Q1 FY27 Earnings Call — Analysis (NSE: PCBL)
PCBL Chemical reports strong Q1FY27 with 23% EBITDA growth, driven by inventory gains and favorable trade shifts, but flags a softer Q2 ahead.
The take
Q1FY27 Consolidated revenue ₹2,474 Cr ( +17% YoY ) . New guidance — FY27 carbon black total sales volume… high single-digit % . New story: Specialty carbon black expansion .
Results
Consolidated revenue ₹2,474 Cr +17% YoY; EBITDA ₹400 Cr +23% YoY; PAT ₹155 Cr +65% YoY.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Consolidated revenue | ₹2,474 Cr | +17% | yoy · Q1FY27 |
| Consolidated EBITDA | ₹400 Cr | +23% | yoy · Q1FY27 |
| Consolidated PAT | ₹155 Cr | +65% | yoy · Q1FY27 |
| Carbon black sales volume | 153,513 MT | yoy · Q1FY27 · steady | |
| Domestic carbon black volume | 102,985 MT | +15% | yoy · Q1FY27 |
| Specialty carbon black volume | 19,748 MT | +23% | yoy · Q1FY27 |
| Aquapharm revenue | ₹394 Cr | point_in_time · Q1FY27 | |
| Aquapharm EBITDA | ₹47 Cr | point_in_time · Q1FY27 | |
| Power EBIT | ₹110 Cr | +₹30 Cr | qoq · Q1FY27 · ₹80 Cr in Q4FY26 |
| Power realisation | ₹5.39/unit | +₹1.73/unit | qoq · Q1FY27 · ₹3.66/unit in Q4FY26 |
Guidance
Full-year carbon black EBITDA/ton improvement of 14–15% over FY26 reiterated (around ₹16,500–17,000/ton); high single-digit volume growth for FY27 confirmed.
What management committed to
- FY27 carbon black EBITDA per ton will improve 14–15% over FY26, reaching approximately ₹16,500–17,000 per ton. — ₹16,500–17,000 per ton (14–15% improvement), FY27
- Carbon black sales volume will grow in high single-digit percentage range in FY27. — high single-digit %, FY27
- Cumulative cost savings of ₹200–250 Cr will be delivered over the next 4 to 6 quarters (from Q1FY27) through the efficiency and feedstock diversification programme. — ₹200–250 Cr, over the next 4 to 6 quarters
- FY27 capex will be approximately ₹300 Cr, +/- ₹50 Cr, primarily maintenance and efficiency capex. — ₹300 Cr ± ₹50 Cr, FY27
- US tariff refund of approximately ₹40–45 Cr (combined PCBL and Aquapharm) will be received within 2 to 4 weeks from the call date (29 July 2026). — ₹40–45 Cr, next 2 to 4 weeks
- Management expects to obtain final capex approval for the coal tar distillation project within the current quarter (Q2FY27). — Q2FY27
- Aquapharm is discussing a new green chelates manufacturing facility because order booking is running ahead of existing capacity.
- Aquapharm full-year FY27 EBITDA per ton will remain similar to Q1FY27 levels (approximately ₹20,000–21,000/ton), though Q2 may be softer. — similar to Q1FY27 (~₹20,000–21,000/ton), FY27
- Nanovace pilot plant will begin customer sampling in August 2026. — Q2FY27
Key themes
Structural tailwinds and specialty expansion
How the narrative shifted
- India’s trade deal tailwinds: Management argues that India’s new FTAs with EU, U.K., and improved U.S. tariff terms give PCBL a structural advantage over competing carbon black exporters.
- Russian supply contraction: Ukrainian strikes on Russian refineries have reduced CBFS supply and Russia’s own carbon black exports, opening market share for Indian producers in Europe and Americas.
- Domestic tire capex cycle: Indian tire makers are running at high utilization and adding capacity, providing visibility for carbon black volume growth, supported by rising tire exports.
- Specialty carbon black expansion: PCBL commissioned a 20 KTPA specialty line and sees global demand shifting to higher-grade, performance-differentiated products, validating its innovation push.
- Battery materials platform build-out: The company is investing in silicon-based anodes (Nanovace) and high-performance conductive carbons (super-conductive, acetylene black) to capture long-term electrification trends.
- Aquapharm turnaround under new CEO: New CEO Rohit Narang outlines growth pillars (new products, U.S. focus, green chelates qualification) while acknowledging oil & gas volatility and near-term raw material pressures.
- Cost efficiency and feedstock integration: The ongoing cost optimisation programme targets ₹200–250 Cr savings over 4–6 quarters, while the coal tar distillation project is being finalised to backward integrate.
- Near-term volume softness from destocking: Management flags that Q2 may see a temporary volume effect as some domestic customers adopt cautious procurement, but frames it as a timing issue, not demand destruction.
Operational commentary
- Commissioned 20,000 MTPA specialty carbon black line in Mundra, taking total installed capacity to 900,000 MTPA.
- Nanovace pilot plant in Palej: R&D consent received, individual machine trials underway, customer sampling expected to start in August 2026.
- 1,000 MTPA super-conductive specialty black facility set up in Palej; market development commenced for battery, conductive polymers and electronics applications.
- Acetylene black project: engineering for first phase completed, product development initiated with technology collaborator.
- New CEO appointed for Aquapharm Chemicals (Rohit Narang, ex-Eastman Chemicals) to drive growth and operational efficiency.
- US tariff refund applications filed for ~₹40–45 Cr (PCBL + Aquapharm) relating to previously paid tariffs; receipt expected in 2–4 weeks.
- Coal tar distillation project under active planning; final capex approval expected within the current quarter (Q2FY27).
- Aquapharm green chelates: order booking running ahead of existing capacity; discussions underway for a new manufacturing facility to meet demand.
- Aquapharm won a new 3-year anti-scaling contract in Saudi Arabia and is expanding reverse osmosis portfolio for the seawater desalination shift.
- Cost optimisation programme on track to deliver cumulative savings of ₹200–250 Cr over the next 4–6 quarters.
Analyst Q&A
Q. What was the quantum of inventory gains this quarter, and what reversal is expected next quarter?
Raj Gupta: We had close to ₹70 Cr of low-cost inventory benefit; about ₹40–50 Cr may reverse next quarter as inventory positions change.
Q. What is the status and quantum of US tariff refunds?
Raj Gupta: Between PCBL and Aquapharm, the amount is ~₹40–45 Cr. We have applied and expect to receive the refund in the next 2–4 weeks.
Q. What is the sustainable EBITDA per kg for Aquapharm, and how should we model it?
Raj Gupta: Q1 EBITDA/ton was ~₹20,500 vs ₹19,500 in the same quarter last year. It is sustainable, though Q2 may be a little lower due to inventory adjustment. Full year should be similar. Nilesh Koul added that the new CEO will develop a detailed plan in coming quarters.
Q. Do you still hold the ₹75 Cr EBITDA exit run rate target for Aquapharm in FY27?
Rohit Narang: It is early days for me. I am trying to understand the stable run rate and will provide more details in subsequent quarters.
Research and educational content only. Not investment advice.